Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
about
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaPreserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphomaR-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphomaAnti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Cancer radioimmunotherapy.Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumorsPlitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximabα-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas.Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 StudyA re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.Peptide vaccines for patients with acute myeloid leukemia.Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Diversity in antibody-based approaches to non-Hodgkin lymphoma.Radioactive antibodies: a historical review of selective targeting and treatment of cancer.Radioimmunotherapy of solid tumors: searching for the right target.Follicular lymphoma: the case for timely intervention.Radioimmunotherapy in mantle cell lymphoma.Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.Radioimmunotherapy in allogeneic nonmyeloablative conditioning for B cell lymphoma: should we use it more often?Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop.Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.Emerging classes of armed antibody therapeutics against cancer
P2860
Q24633710-8C50ACEC-2D07-43A0-B7CC-1212AD078468Q30764873-B0DE3AD4-A691-4813-8891-B5A77C92727EQ33605275-3D03C23D-0FDB-41B6-9A23-320C30D80B81Q33645793-EAE8E5A9-867D-493B-84F7-F78B0492BA61Q33915986-0D03D752-FF0B-4118-A17B-FF80DEBC8BBBQ33934326-A88FF08D-3CB5-4D33-BAF9-C6DB3981FD4AQ34318792-B2AD08DF-713D-4550-81B1-CC977A4B776DQ34463593-F8624331-8C33-4649-A309-66DDFC691A31Q34498655-B9B41DFD-5FDD-4C5B-A251-5F17B15A704CQ34876695-5D5D3FFA-0032-412C-83A1-6F47193DB302Q35070045-92524457-F362-4D4B-AE09-3D2A3FC15FDCQ35650530-9DC58E03-DC1E-4DB3-B1DD-F89F5301C073Q35911656-05DF5929-BB44-46DF-841E-F37288CCCB09Q36362587-FA4FBAD6-03D3-49AD-A012-50099F637F6EQ36905562-33C21DAE-35F0-4FDD-AE19-3962F1522EF8Q36979074-345A7BF7-51CF-44BC-AA34-AFEAF471463AQ37065959-FCD95BF9-8527-4F2E-8706-0982AEDE41CFQ37158257-0B6F8FAD-9641-475E-B595-EA32878035D9Q37169112-0394BC7F-E05D-4D09-A3EC-97FA333484FEQ37201878-D703DA67-2183-4517-B7D3-2D4114BB757CQ37237469-E91D93DD-138C-4D4B-8729-4B77ABF5C733Q37295150-580105B0-B292-4C39-AED1-6F263A973AFEQ37608316-649499D1-B3F1-42F4-B029-51C1E804DD4BQ37663837-CC4E1795-5072-4C87-90F6-CC2590A204F9Q37752447-2173E19F-0B80-4447-A19F-06808A95754AQ37785097-4D46978E-A484-458B-B75E-BBA2074BBFF2Q37796519-470EE862-CCD2-4418-94D3-17F35AB02AD8Q37804904-2B11569B-E62E-4357-B600-DDBA55C8E47BQ37810093-7EDB78F6-5418-47E1-9C87-D7D317F63813Q38017790-E8F64215-61DC-408C-BD9A-CACEBC01C0FCQ39564060-EEB9C2BA-54F8-402B-8735-035C5818BB96Q40150317-665E51EC-2BFF-45BB-B1EE-A898746F7916Q41945014-6E722AFB-78C8-4C16-B81E-3C11444545BFQ42683016-236FA7E0-FE8F-41CE-9709-573F56F6069BQ43167275-29520627-D776-4AD6-AA37-25D7DC599DF3Q44953022-339A2C39-373F-4888-B112-949E86477D18Q48260192-AD359EA1-8D5F-4A3B-99F6-2679E9A77C64Q50146121-E4DF2C33-D3EF-48F1-BBB4-9207C1A5BE9DQ52689720-53F10706-87DA-421E-A062-99406CFB86A5Q57911948-69A88E79-A69D-4995-AF8E-BF2619C7B024
P2860
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Rituximab blocks binding of ra ...... not radiolabeled anti-CD45 Ab.
@en
type
label
Rituximab blocks binding of ra ...... not radiolabeled anti-CD45 Ab.
@en
prefLabel
Rituximab blocks binding of ra ...... not radiolabeled anti-CD45 Ab.
@en
P2093
P2860
P1433
P1476
Rituximab blocks binding of ra ...... not radiolabeled anti-CD45 Ab
@en
P2093
David G Maloney
John M Pagel
Shani M Wilbur
P2860
P304
P356
10.1182/BLOOD-2008-01-132142
P407
P577
2008-05-23T00:00:00Z